Biarylmethyl indolines and indoles as antithromboembolic agents
    21.
    发明授权
    Biarylmethyl indolines and indoles as antithromboembolic agents 有权
    二芳基甲基中吲哚和吲哚作为抗血栓栓剂

    公开(公告)号:US07129264B2

    公开(公告)日:2006-10-31

    申请号:US10824025

    申请日:2004-04-14

    CPC分类号: C07D209/08 C07D209/22

    摘要: The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt or hydrate form thereof, wherein the variables A, B, L1, L2, X1, X2, X3, X4 and W are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

    摘要翻译: 本发明提供式(I)化合物或其立体异构体或药学上可接受的盐或水合物形式,其中变量A,B,L 1,L 2, X 1,X 2,X 3,X 4和W如本文所定义。 式(I)的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶的选择性抑制剂; 例如凝血酶,因子Xa,因子XIa,因子IXa,因子VIIa和/或血浆激肽释放酶。 特别地,它涉及作为选择性因子XIa抑制剂的化合物。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。

    Isoxazoline fibrinogen receptor antagonists
    24.
    发明授权
    Isoxazoline fibrinogen receptor antagonists 有权
    异恶唑啉纤维蛋白原受体拮抗剂

    公开(公告)号:US06476226B2

    公开(公告)日:2002-11-05

    申请号:US09905321

    申请日:2001-07-13

    IPC分类号: C07D21500

    摘要: This invention relates to novel isoxazolines and isoxazoles of formula (I): or a pharmaceutically acceptable salt or prodrug form thereof. The invention relates to novel isoxazolines which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

    摘要翻译: 本发明涉及新的式(I)的异恶唑和异恶唑:或其药学上可接受的盐或前药形式。 本发明涉及可用作血小板糖蛋白IIb / IIIa纤维蛋白原受体复合物的拮抗剂的新型异恶唑类,含有这些化合物的药物组合物,制备这些化合物的方法,以及使用这些化合物单独或与其它治疗剂 用于抑制血小板聚集,作为血栓溶解剂,和/或用于治疗血栓栓塞性疾病。

    Substituted bicyclic phosphoramides and derivatives thereof
    25.
    发明授权
    Substituted bicyclic phosphoramides and derivatives thereof 失效
    取代的双环磷酰胺及其衍生物

    公开(公告)号:US5543517A

    公开(公告)日:1996-08-06

    申请号:US181117

    申请日:1994-01-13

    CPC分类号: C07F9/65848

    摘要: This invention relates to substituted bicyclic phosphoramides and derivatives thereof, useful as retroviral protease inhibitors and as standards and reagents in determining the ability of a potential pharmaceutical to inhibit viral replication or HIV protease, to pharmaceutical compositions comprising such compounds, and to methods of using these compounds for treating viral infection.

    摘要翻译: 本发明涉及可用作逆转录病毒蛋白酶抑制剂的取代的双环磷酰胺及其衍生物,以及用于确定潜在药物抑制病毒复制或HIV蛋白酶的能力的标准和试剂,包含这些化合物的药物组合物,以及使用这些化合物的方法 用于治疗病毒感染的化合物。

    Isoxazoline fibrinogen receptor antagonists
    28.
    发明授权
    Isoxazoline fibrinogen receptor antagonists 有权
    异恶唑啉纤维蛋白原受体拮抗剂

    公开(公告)号:US06303609B1

    公开(公告)日:2001-10-16

    申请号:US09442682

    申请日:1999-11-18

    IPC分类号: A61K31495

    摘要: This invention relates to novel isoxazolines and isoxazoles of formula (I): or a pharmaceutically acceptable salt or prodrug form thereof. The invention relates to novel isoxazolines which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

    摘要翻译: 本发明涉及新的式(I)的异恶唑和异恶唑:或其药学上可接受的盐或前药形式。 本发明涉及可用作血小板糖蛋白IIb / IIIa纤维蛋白原受体复合物的拮抗剂的新型异恶唑类,含有这些化合物的药物组合物,制备这些化合物的方法,以及使用这些化合物单独或与其它治疗剂 用于抑制血小板聚集,作为血栓溶解剂,和/或用于治疗血栓栓塞性疾病。